Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
about
Dose and frequency titration of somatostatin analogues in the treatment of acromegaly - an injection of expediency?Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review.Management of acromegaly in Latin America: expert panel recommendationsThe endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome.Current pharmacotherapy for acromegaly: a review.From somatostatin to octreotide LAR: evolution of a somatostatin analogueControl of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.Octreotide LAR: safety and tolerability issues.Octreotide for acromegaly treatment: a reappraisal.Adverse events associated with somatostatin analogs in acromegaly.Men with acromegaly need higher doses of octreotide than women.Effects of two different somatostatin analogs on glucose tolerance in acromegaly.Treatment of an acromegalic cat with the dopamine agonist L-deprenyl.Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study.Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles.Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
P2860
Q31894010-BBEDE8A9-4C20-4DE1-B7EF-85F3E2993FA1Q33772673-7CA0B88A-5938-4B32-BB50-2769030F3569Q33794388-65AEB9A0-3DCF-4075-A601-4BF550CB7C0FQ34031906-0FDDDCE0-86BF-4A06-AFF8-C437AFB2ED40Q36301564-9090B500-BC0C-4B06-B755-44FBE4610740Q36919554-B38E697E-94C2-4D16-AAD5-234D1D4F4DFCQ37029532-7D31CBE7-00A0-4CCD-9D93-0AEEA3D9773EQ37649647-E7B27051-F2ED-4AEA-8E0F-E82CC5CF9DCDQ38152458-55D2F27B-2EBF-4E82-A29A-6A76AE207601Q38548973-744A7454-AE3B-4067-B948-953C0F9BBE3BQ43889400-28E0A461-D603-480F-B0B3-18B57318522DQ44057154-E32C461D-47F3-4FB6-B4F9-B19C01024496Q44132936-DCDB323C-B2DE-43E4-89A9-FCCE29CCA4E3Q44331741-E3135FE8-2C6D-4F4D-B0B3-A9ED3D8A919EQ44992381-FB403CD6-41D0-4CDA-87B8-5D01B1D9B488Q45101617-D6809902-B8F8-4B83-91D0-4CE02FEB6187Q46147583-6FB450AF-A86A-4A1B-AA4C-43B15F8D072CQ46542233-3B16CE48-9CFD-4130-9603-2524A00B54ADQ51750907-112B34C1-ABD6-4DF8-8F78-4038DC787908
P2860
Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Optimal dosage interval for de ...... requires individual titration.
@ast
Optimal dosage interval for de ...... requires individual titration.
@en
type
label
Optimal dosage interval for de ...... requires individual titration.
@ast
Optimal dosage interval for de ...... requires individual titration.
@en
prefLabel
Optimal dosage interval for de ...... requires individual titration.
@ast
Optimal dosage interval for de ...... requires individual titration.
@en
P2093
P2860
P1476
Optimal dosage interval for de ...... requires individual titration.
@en
P2093
P2860
P304
P356
10.1046/J.1365-2265.2000.01168.X
P577
2000-12-01T00:00:00Z